Anticancer Activity Discovered in Dozens of Existing Noncancer Drugs

The Broad Institute of MIT and Harvard
300 Binney Street
Cambridge, MA 02142

PRISM cancer cell viability profiling enables insights into clinical candidate target selectivity: A case study revealing the most selective PRMT5 inhibitors for cancers with MTAP loss – Abstract | Poster
Accelerating the development of biologics: PRISM high throughput screening enables rapid preclinical characterization of antibodies, ADCs and payloads – Abstract | Poster
A cellular platform for systematic comparison of RAS inhibitors using PRISM multiplexed screening – Abstract | Poster